Floatz logo

Autologous Anti-Cd19 Car-Expressing T Lymphocytes

Paraganglioma

Anusha KalbasiCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Paraganglioma cohort.

Asset / SponsorPhaseRating
Oxodotreotide
Fundación de investigación HM
Phase 2B
Talzenna
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Guadecitabine
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

Autologous Anti-Cd19 Car-Expressing T Lymphocytes is also rated in:

pheochromocytomaDormant
CC
Indicative ·
43 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
43 / 100
View asset →
adrenal cortex carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →